P, J., V, F., S, R., A, C., L, M., V, A., . . . J, G. (2023). The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. SAGE PUBLICATIONS LTD.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
P, Jimenez-Fonseca, et al. The AGAMENON-SEOM Model for Prediction of Survival in Patients with Advanced HER2-positive Oesophagogastric Adenocarcinoma Receiving First-line Trastuzumab-based Therapy. SAGE PUBLICATIONS LTD, 2023.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
P, Jimenez-Fonseca, et al. The AGAMENON-SEOM Model for Prediction of Survival in Patients with Advanced HER2-positive Oesophagogastric Adenocarcinoma Receiving First-line Trastuzumab-based Therapy. SAGE PUBLICATIONS LTD, 2023.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.